HER3 expression is correlated to distally located and low-grade colon cancer

References

• National Cancer Institute, www.cancer.gov/types/colorectal/hp/colon-treatment-pdq. 2015.
   Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res 2006;12:5268–72.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82.
   PubMed Web of Science ®Google Scholar
• Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000;19:6102–14.
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J 1997;16:1647–55.
   PubMed Web of Science ®Google Scholar
• Beji A, Horst D, Engel J, Kirchner T, Ullrich A. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 2012;18:956–68.
   PubMed Web of Science ®Google Scholar
• Ocana A, Vera-Badillo F, Seruga B, Templeton A, Pandiella A, Amir E. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst 2013;105:266–73.
   PubMedGoogle Scholar
• Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, et al. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol Cancer 2013;12:134.
   PubMed Web of Science ®Google Scholar
• Lédel F, Hallström M, Ragnhammar P, Ohrling K, Edler D. HER3 expression in patients with primary colorectal cancer and corresponding lymph node metastases related to clinical outcome. Eur J Cancer 2013;50:656–662.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005;44:904–12. Erratum in: Acta Oncol. 2006;45(1):110.
   PubMed Web of Science ®Google Scholar
• Mcshane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, et al. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005;2:416–22.
   PubMedGoogle Scholar
• Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res 2015;17:53.
   PubMed Web of Science ®Google Scholar
• Sargent D, Wieand H, Haller D, Gray R, Benedetti J, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664–70.
   PubMed Web of Science ®Google Scholar
• Ljuslinder I, Malmer B, Isaksson-Mettavainio M, Oberg A, Henriksson R, Stenling R, et al. ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Res 2009;29:1489–94.
   PubMed Web of Science ®Google Scholar
• Kountourakis P, Pavlakis K, Psyrri Rontogianni AA, Xiros DN, Patsouris E, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006;6:46.
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Jacobs B, D'ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014;25:1995–2001.
   PubMed Web of Science ®Google Scholar
• Greystoke A, Mullamitha SA. How many diseases are colorectal cancer? Gastroenterol Res Pract. 2012;2012:564741.
   PubMed Web of Science ®Google Scholar
• Lee GH, Malietzis G, Askari A, Bernardo D, Al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - A systematic review. Eur J Surg Oncol 2015;41:300–8.
   PubMed Web of Science ®Google Scholar
• Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010;53:57–64.
   PubMed Web of Science ®Google Scholar
• Brule SY. Jonker DJ, Karapetis CS, O’Callaghan CJ, Moore MJ, Wong R, et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET). J Clin Oncol 31, (suppl; abstr 3528). Epub 2013 ASCO Annual Meeting.
   Web of Science ®Google Scholar
• Cushman S, Jiang C, Hatch A, Shterev I, Sibley A, Niedzwiecki D, et al. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 2015;21:1078–1086.
   PubMed Web of Science ®Google Scholar
• Gaborit N, Abdul-Hai A, Mancini M, Lindzen M, Lavi S, Leitner O, et al. Examination of HER3 targeting in cancer using monoclonal antibodies. Proc Natl Acad Sci USA 2015;112:839–44.
   PubMed Web of Science ®Google Scholar
• Ma J, Lyu H, Huang J, Liu B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer 2014;13:105 Review.
   PubMed Web of Science ®Google Scholar
• Nakata S, Tanaka H, Ito Y, Hara M, Fujita M, Kondo E, et al. Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity. Int J Oncol 2014;45:1583–93.
   PubMed Web of Science ®Google Scholar
• Gala K, Chandarlapaty S. Molecular pathways: HER3 targeted therapy. Clin Cancer Res 2014;20:1410–6.
   PubMed Web of Science ®Google Scholar